Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hamburg sees Zicam action as "good outcome"

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Margaret Hamburg views the 2009 removal of intranasal zinc-containing Zicam products from store shelves as a good example of how the agency is more prevention-focused. After FDA learned of more than 130 cases of anosmia associated with the Matrixx Initiatives products, the agency "warned consumers not to use these products and the manufacturer removed them from the shelves a week later," Hamburg said Feb. 8 at the National Health Policy Conference in Washington. "This was a good outcome," she said, adding that in the past, FDA "found itself engaging in back-and-forths with companies and with lawyers while serious health and safety problems remained in limbo." Matrixx recently sued FDA for information about the call for removal of its top-selling Zicam products (1"The Tan Sheet" Feb. 1, 2010)

You may also be interested in...



Matrixx disputes Hamburg comments

FDA unfairly asked Matrixx Initiatives to recall its intranasal Zicam products with zinc, the firm argues. In response to Commissioner Margaret Hamburg's Feb. 8 comment that the agency's Zicam actions led to "a good outcome," Matrixx CEO William Hemelt says, "FDA made a major mistake that deprived the public of an effective and safe treatment for colds" (1"The Tan Sheet" Feb. 15, 2010, In Brief). Hemelt says in a Feb. 24 2letter the agency's reliance on previously rejected evidence linking zinc to anosmia and failure to engage with Matrixx "did a serious disservice to the truth, and also to due process." Hemelt added FDA's refusal to share documentation supporting its actions is inconsistent "with your attempts to restore confidence in the integrity of the agency.

Matrixx Initiatives Files Suit Against FDA On Unanswered FOIA Grounds

Matrixx Initiatives is suing FDA for the release of information related to the recall of its Zicam zinc-containing intranasal cold remedy products from the market

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

UsernamePublicRestriction

Register

PS103799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel